Figure 1: Top 10 Selling Products of Amgen (US$ mill)

Source: GlobalData, Pharma Intelligence Center, [Accessed 19th Dec 2017]

Figure 1 displays the sales values of the top ten products of Amgen for 2016. Enbrel and Neulasta are the best performing drugs by a large margin; however, many of their other drugs are also top performers. There top 7 drugs all make over 1,000 (US$m). Going forward Enbrel and Neulasta revenues are expected to half by 2023 meaning Amgen position may not be as strong going forward, but Amgen are expecting another high performing drug in Repatha; expected to be valued at 3,440 (US$m) by 2023.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.